Last reviewed · How we verify
Halopyramine (CHLOROPYRAMINE)
Halopyramine (generic name: CHLOROPYRAMINE) is a chloropyramine drug. It is currently in Phase 2 development.
Halopyramine works by inhibiting focal adhesion kinase 1, a protein involved in cell signaling and adhesion.
Halopyramine (CHLOROPYRAMINE) is a small molecule drug that targets focal adhesion kinase 1. It belongs to the chloropyramine class and its mechanism of action is not well-documented. There is limited information available on its commercial status, approved indications, and pharmacokinetic properties. Further research is needed to understand its potential therapeutic applications and safety profile. As a result, it is not possible to provide a comprehensive summary of this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CHLOROPYRAMINE |
|---|---|
| Drug class | chloropyramine |
| Target | Focal adhesion kinase 1 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Think of focal adhesion kinase 1 like a messenger that helps cells stick together and communicate with each other. Halopyramine blocks this messenger, which can affect how cells behave and interact with their environment. This can potentially lead to changes in cell growth, movement, and other cellular processes.
Approved indications
Common side effects
- Vaccination site reaction
- Carcinoembryonic antigen
- Carbohydrate antigen 15-3
- Pleural neoplasm
- Cranial nerve disorder
- Bacteriuria
- Right ventricular dilatation
- Thyroid mass
- Body temperature increased
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Halopyramine CI brief — competitive landscape report
- Halopyramine updates RSS · CI watch RSS
Frequently asked questions about Halopyramine
What is Halopyramine?
How does Halopyramine work?
What is the generic name of Halopyramine?
What drug class is Halopyramine in?
What development phase is Halopyramine in?
What are the side effects of Halopyramine?
What does Halopyramine target?
Related
- Drug class: All chloropyramine drugs
- Target: All drugs targeting Focal adhesion kinase 1
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing